Issue Date: July 22, 2013
Merck Serono Pens Diagnostics Deal
Merck Serono and instrument maker Life Technologies have signed a nonexclusive agreement to develop diagnostic tests to complement Merck’s drugs. The two intend to focus on oncology initially, but they expect to broaden their efforts to cover a range of therapeutic areas. They also plan to work together to win regulatory approval for new drugs and companion diagnostics. Life and Bristol-Myers Squibb reached a similar deal last . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society